Artimplant key ratios January - December 2006-2010
| Amounts in SEK thousands |
Jan-Dec 2010 |
Jan-Dec 2009
|
Jan-Dec 2008 |
Jan-Dec
2007 |
Jan-Dec
2006 |
| Equity per stock unit, SEK |
0.29 |
0.40 |
0.71 |
1.08 |
1.31 |
| Equity per stock unit after dilution, SEK |
0.29 |
0.40 |
0.71 |
1.08 |
1.31 |
| Loss per stock unit, SEK |
0,32 |
0.31 |
0.38 |
0.23 |
0.95 |
| Loss per stock unit after dilution, SEK |
0.32 |
0.31 |
0.38 |
0.23 |
0.95 |
| No. of stock units in issue at year-end |
118,489,580 |
59,244,790 |
59,244,790 |
59,244,790 |
59,244,790 |
| Average no. of stock units in issue during year |
69,118,922 |
59,244,790 |
59,244,790 |
59,244,790 |
59,244,790 |
| No. of stock units in issue after dilution |
120,532,181 |
61,346,566 |
60,793,246 |
60,446,582 |
60,348,628 |
| Average no. of stock units in issue after dilution |
71,161,523 |
61,346,566 |
60,793,246
|
60,446,582
|
60,348,628
|
| Cash flow per stock unit, SEK |
0.31
|
-0.27
|
-0.30
|
-0.33
|
-0,60
|
| Dividend per stock unit, SEK1 |
-
|
-
|
-
|
-
|
-
|
| Market price, highest, SEK |
2.16 |
2.90 |
3.53 |
6.28 |
8.44 |
| Market price, lowest, SEK |
0.61 |
1,08 |
1.29 |
2.58 |
2.28 |
| Market price as of Jan 1, SEK |
1.57 |
1,36 |
2.76 |
3.04 |
7.03 |
| Market price as of Dec 31, SEK |
0.66 |
1,57 |
1.36 |
2.76 |
3.04 |
| Return on equity, % |
Neg
|
Neg
|
Neg
|
Neg
|
Neg
|
| Return on capital employed, % |
Neg
|
Neg
|
Neg
|
Neg
|
Neg
|
| Return on capital, % |
Neg |
Neg |
Neg |
Neg |
Neg |
| Equity/assets ratio, % |
73
|
78
|
92
|
92
|
93
|
| Proportion of risk capital, % |
73
|
78
|
92
|
92
|
93
|
| Interest-bearing liabilities |
4,000
|
None
|
None
|
None
|
None
|
Interest coverage ratio
|
Neg
|
Neg
|
Neg
|
Neg
|
Neg
|
| Financial net assets |
32,890
|
15,613
|
31,371
|
49,240
|
68,704
|
| Capital expenditure |
|
|
|
| Research and development2 |
-
|
-
|
-
|
-
|
480
|
| Patents and brands |
226
|
215
|
471
|
3,236
|
646
|
Machinery and equipment
|
39 |
25 |
129 |
627 |
1,165 |
| Number of employees |
|
|
|
|
|
| No. of employees as of Dec 31 |
25
|
25
|
28
|
25
|
28
|
| |
|
|
|
|
|
The impact of dilution has not been reported in those cases where dilution would have resulted in an improvement in the key ratios.
1) For 2010, the figure refers to the proposal by the Board of Directors.
2) Investment in product development according to IAS 38. With effect from 2007, product development expenses are not capitalized.
|
